Robert Roe explores the role of maintenance in ensuring HPC systems run at optimal performance
Robert Roe talks to Southampton University’s Oz Parchment about the decision-making behind the latest HPC system at the University
Cloud bursting is revolutionising research at universities writes Mahesh Pancholi, Research Computing Specialist at OCF
Queen Mary University of London (QMUL) and Newcastle University, are the first UK academic organisations to deploy servers containing IBM’s POWER9 system
Researchers from across the University of Southampton are benefitting from a new High Performance Computing (HPC) machine named Iridis, which has entered the TOP500, debuting at 251 on the list.
Robert Roe looks at the role of integrators to deliver and support HPC systems
David Yip, HPC and Storage Business Development at OCF, provides his take on the place of GPU technology in HPC.
Robert Roe talks to cooling experts to find out what innovation lies ahead for HPC users
OCF has successfully achieved Elite Partner status with NVIDIA I the competency of Accelerated Computing.
Robert Roe finds that commoditisation of flash and SSD technology and the uptake of machine learning and AI applications are driving new paradigms in storage technology.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
